Cash and Cash Equivalents: As of September 30, 2024, Senti Bio held cash and cash equivalents of $10.5 million. Subsequent to quarter-end, the Company received $2.5 million, the second tranche of an ...

The global neuroendocrine carcinoma treatment market is poised for substantial growth, with revenue expected to reach USD ...

A GRASSINGTON woman conquered her fear of heights and took to the skies in a glider to raise money for a cancer charity close ...